Related Experiment Videos
The use of acyclovir in suspected encephalitis
Journal of the Royal Society of Medicine
|January 1, 1994
Summary
Early intravenous acyclovir is crucial for herpes simplex encephalitis (HSE). This study suggests guidelines to minimize costs while ensuring timely treatment for suspected HSE cases, given diagnostic limitations.
Area of Science:
- Neurology
- Infectious Diseases
- Pharmacology
Background:
- Herpes simplex encephalitis (HSE) requires prompt treatment with intravenous acyclovir.
- Rapid diagnostic tools for HSE are not widely accessible, leading to empirical treatment decisions.
- Empirical acyclovir use in suspected encephalitis cases can be costly and may lead to overtreatment.
Purpose of the Study:
- To develop guidelines for acyclovir use in suspected encephalitis.
- To balance the need for early HSE treatment with the economic implications of empirical therapy.
- To optimize acyclovir administration in resource-limited settings.
Main Methods:
- Retrospective analysis of 34 patients with suspected encephalitis.
- Review of diagnostic outcomes, including confirmed HSE, other encephalitis causes, and non-encephalitis diagnoses.
- Development of clinical guidelines based on diagnostic yield and treatment necessity.
Main Results:
- Only 2 out of 34 patients (approx. 6%) with suspected encephalitis were confirmed to have HSE.
- 19 patients (approx. 56%) had encephalitis from other causes.
- 13 patients (approx. 38%) were diagnosed with non-encephalitic illnesses.
Conclusions:
- Empirical acyclovir use in all suspected encephalitis cases results in significant overtreatment.
- Guidelines are proposed to refine acyclovir initiation, reducing costs while safeguarding HSE patients.
- Careful patient selection and diagnostic workup are essential for appropriate acyclovir use in encephalitis.